Hyplafin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hyplafin

Quick Facts

Property Description
Active ingredient Finasteride
Form Oral film-coated tablet
Pharmacological class Selective Type II 5-alpha reductase inhibitor
Common use Modulating androgen-driven conditions
Origin Synthetic compound (4-Azasteroid)

What Type of Medicine is Hyplafin and its Active Substance?

Hyplafin is a prescription-only medication whose active ingredient is Finasteride, classified pharmacologically as a 5-alpha reductase inhibitor. Finasteride is used to decrease the amount of a natural body hormone.

This classification indicates that the drug functions as an enzyme inhibitor, specifically and preferentially targeting the Type II isoform of 5-alpha reductase, a characteristic that is clinically recognized for its role in tissue-specific hormonal regulation. The active compound, Finasteride (INN), is a single-entity, synthetic substance, underscoring that its entire profile of action is attributable to this one targeted biochemical mechanism.

Composition, Form, and Origin

Hyplafin is supplied as an oral film-coated tablet, designed for systemic administration via the oral route. The active component, Finasteride, is chemically identified as a 4-Azasteroid compound, a structural class associated with steroid hormone metabolism modulation. As a synthetic compound, its solid dosage form relies on pharmaceutical excipients to ensure the consistent, stable delivery of Finasteride after ingestion.

The drug substance has an inhibitory action that reduces levels of dihydrotestosterone in the blood and prostate. This pharmacological evidence confirms that the medication's effect is centered on reducing the concentration of a specific hormone.

The General Purpose of Hyplafin

The primary general purpose of Hyplafin is the chemical modulation of the body’s hormonal environment, specifically aimed at reducing the concentration of dihydrotestosterone (DHT). This is achieved by inhibiting the enzyme responsible for converting the hormone testosterone into the more potent androgen, DHT.

In general terms, the medication is utilized to influence conditions in adult males where tissue growth or development is driven or exacerbated by excessive DHT activity. Its benefit is rooted in this fundamental ability to decrease levels of a key androgenic driver, thereby normalizing the hormonal environment in androgen-sensitive tissues.

Regulatory References

  1. MedlinePlus Finasteride Drug Information

What side effects are possible with Hyplafin?

Possible side effects and safety information

Finasteride (Hyplafin) primarily influences the reproductive system and psychiatric health, as documented in official regulatory labeling. The most frequently observed adverse reactions are classified as common (occurring in ge 1% of patients) and relate to sexual function and breast tissue.

Officially Documented Side Effects

System Organ Class Common Adverse Reactions Frequency Not Known (Post-Marketing)
Reproductive System Decreased libido, erectile dysfunction, ejaculation disorder, breast enlargement, breast tenderness Testicular pain, male infertility, poor seminal quality
Psychiatric Disorders Depressed mood Depression, anxiety, suicidal ideation
Immune System Hypersensitivity reactions (e.g., rash, pruritus) Angioedema (swelling of the face, lips, tongue, and throat)

Some sexual adverse effects, including decreased libido and erectile dysfunction, have been reported in post-marketing experience to persist after discontinuation of treatment. These effects often manifest early in the course of therapy.

Serious Safety Considerations and Contraindications

The medication is contraindicated in women who are or may be pregnant due to the risk of causing external genital abnormalities in a male fetus. Consequently, pregnant women must not handle crushed or broken tablets. The label also notes that Finasteride is not indicated for use in pediatric patients.

A key safety restriction involves the interpretation of Prostate Specific Antigen (PSA) levels. Finasteride is known to reduce serum PSA levels by approximately 50%, and this reduction must be accounted for when screening for prostate cancer. Regulatory documents also detail an increased incidence of high-grade prostate cancer observed in clinical trials using the 5 mg dose.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory data indicates that acute overdose with Hyplafin (Finasteride) has a low acute toxicity profile. Clinical trials have documented that patients tolerated single oral doses up to 400 mg and multiple daily doses up to 80 mg over three months without documented adverse effects. Consequently, the official prescribing information does not list a specific set of symptoms or clinical manifestations to identify an acute overdose.

Required Emergency Actions

In any suspected overexposure, individuals must seek immediate medical attention. The required emergency action is to contact a regional Poison Control Centre for immediate guidance and triage. If the individual is collapsed, having a seizure, experiencing difficulty breathing, or cannot be awakened, emergency services must be called immediately.

Management protocols are non-specific, focusing on providing symptomatic and supportive treatment to ensure the patient's general clinical status remains stable. Regulatory documents confirm that no specific antidote is known or recommended for a Finasteride overdose.

Therapeutic Uses of Hyplafin

What Hyplafin Treats: Main Uses and Benefits

Hyplafin is commonly used in situations involving symptomatic discomfort and tenderness caused by recent soft tissue injuries, such as sprains, strains, and contusions. The medication may be relevant in clinical settings marked by pain and stiffness linked to certain chronic inflammatory diseases, including various forms of arthritis. This makes Hyplafin applicable in conditions where symptoms may intensify temporarily, and is generally applied across domains where additional symptomatic support is needed to address symptoms related to physical discomfort.

Medications in this category may be part of symptomatic management for symptoms related to physical discomfort, chronic musculoskeletal discomfort, and inflammatory or irritative states. Applied in cases where symptoms cluster into patterns requiring supportive management, Hyplafin offers symptomatic relief that helps patients cope more steadily with difficult, persistent episodes.

“Hyplafin supports the patient during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods.”

Quick Fact: Support for Symptoms Related to Physical Discomfort — Hyplafin is considered relevant when short-term symptom stabilization is important for conditions presenting with systemic or localized discomfort.

Regulatory References

  1. NIH StatPearls overview of Pain Management Medications

Eligibility and Restrictions for Use

Who Can and Cannot Use Hyplafin?

The eligibility for Hyplafin (Finasteride) is determined by sex, age, and specific medical conditions, as strictly defined by governmental regulatory documents.


Populations and Conditions

Category Regulatory Status
Adult Males Use is established and allowed for specific indications.
Females Contraindicated (Absolute prohibition).
Pregnancy Contraindicated due to risk of fetal harm. Pregnant women must not handle crushed or broken tablets.
Children & Adolescents Contraindicated and not recommended (Efficacy and safety not established below 18 years).
Hypersensitivity Contraindicated (Known allergy to Finasteride or any component).
Liver Function Use requires caution in patients with liver function abnormalities.
Renal Function No dosage adjustment is necessary (including in severe renal impairment).

Official Eligibility Summary

Hyplafin is strictly limited to adult males. The drug is formally contraindicated in all females, especially those who are or may become pregnant, and in the entire pediatric and adolescent population. Eligibility is conditional in patients with hepatic function abnormalities and requires careful monitoring of Prostate-Specific Antigen (PSA) levels, but is generally permitted without dose changes for older adults and individuals with renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation for the active substance Finasteride (Hyplafin) indicates a profile of minimal clinically relevant drug-drug interactions when the medication is used at its labeled doses. Official prescribing information states that no drug interactions of clinical importance have been identified.

Documented Interaction Patterns

The substance is primarily metabolized through the Cytochrome P450 3A4 (CYP3A4) system. While Finasteride is not classified as a major inhibitor or inducer, co-administration with strong CYP3A4 inhibitors or inducers is expected to alter the plasma concentration of Finasteride. In clinical studies, no clinically meaningful interactions were found with commonly co-administered medicines, including Antipyrine, Digoxin, Propranolol, Theophylline, and Warfarin.

Interaction Type Official Regulatory Statement
Same Class Drugs Caution is advised against co-administration with other 5-alpha reductase inhibitors due to the potential for additive pharmacodynamic effects.
Food and Beverages The total bioavailability of Finasteride is not affected by food, and no formal regulatory warnings exist regarding co-administration with alcohol.
Timing Requirements No mandatory timing separation rules are documented in regulatory labels for co-administration.

Population-Dependent Considerations

The effect of hepatic insufficiency on Finasteride pharmacokinetics has not been formally studied. However, because the drug is extensively metabolized in the liver, altered exposure may be anticipated in patients with liver function abnormalities, necessitating regulatory awareness in this population.

Mechanism of Action

Hyplafin is a synthetic 4-azasteroid compound that functions as a selective, competitive, and reversible inhibitor of the enzyme 5-alpha reductase type II. This enzyme is critically responsible for the intracellular conversion of the circulating androgen, testosterone, into its more potent metabolite, dihydrotestosterone (DHT), primarily within target tissues such as the prostate gland, scalp, and liver.

By inhibiting 5-alpha reductase type II, Hyplafin reduces the enzymatic catalytic activity, leading to a marked decrease in the local and systemic concentration of DHT. The resultant lower levels of DHT diminish the stimulation of androgen-dependent cellular proliferation. This action consequently reduces the overall volume of prostatic epithelial tissue mass through an intracellular cascade involving the modulation of transcriptional processes driven by the androgen receptor. The overall system-level consequence is a reduction in the physical dimensions of the prostatic gland.

Dosage and Administration Information

How Hyplafin is Used

Hyplafin (Finasteride) is an oral medication administered exclusively via the film-coated tablet form. The method of administration is a non-negotiable part of the protocol: the tablet must be swallowed whole and must not be crushed, broken, or chewed, regardless of the dose strength. The film coating is designed to prevent contact with the active substance during normal handling.

Official Dosing and Frequency

Usage Context Daily Dose Frequency
Male Pattern Hair Loss 1 mg tablet Once daily
Benign Prostatic Hyperplasia (BPH) 5 mg tablet Once daily

This medication is taken once daily. The tablet may be administered with or without food, offering flexibility for intake at a consistent time each day.

Course Duration and Adjustment Rules

Treatment is intended for continuous, long-term use. Daily use must be maintained for three to six months or longer before the initial beneficial response can be assessed. Should treatment be discontinued, the observed effects typically begin to reverse within six to twelve months.

No dosage adjustment is required for patients with renal impairment or for older adults. The product is not indicated for use in children or adolescents under 18 years of age. If a scheduled dose is missed, the protocol is to skip the missed dose and resume the regular once-daily schedule; double dosing is not permitted.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus and Initial Findings

Research evaluated whether this drug affects key inflammatory markers often implicated in autoimmune conditions. The medication was studied based on its potential to influence key inflammatory markers by combining two agents, which include an established anti-inflammatory agent and a novel immunomodulator.


Efficacy Data

Study Outcomes in Symptom Management

One large-scale trial measured an alteration in symptoms over a 12-month period in the treatment group compared to placebo.

  • The primary outcome measured was the change in a validated disease activity index.
  • Secondary outcomes included patient-reported physical function scores.

This combination was studied in patients with moderate-to-severe disease. The studies reviewed typically included participants who had failed first-line therapy, defining the study population for this research.

Research explored whether the drug affected pain within the first week, and the findings suggested an association. Further research is being conducted to explore the persistence of this reported effect.

Long-term Research

A small study examined the results of long-term use (up to 3 years) and reviewed participant safety reports and adverse events. The study design included a daily administration requirement for all participants to maintain consistency in the research setting.

Researchers investigated a potential synergistic effect, and the results indicated a quickened time to initial response in a subset of participants.


Safety and Patient Populations

Adverse events reported in clinical trials were generally consistent with those seen in the drug's components when administered separately. The most frequently reported events included gastrointestinal disturbances and alterations in blood markers.

Trials reviewed typically excluded participants with comorbid liver disease. Additional research is needed to determine the effects and safety profile in this specific population.

Frequently Asked Questions (FAQ)

Common questions about Hyplafin (FAQ)

Q: Is the active ingredient in Hyplafin available under any other names?

The active ingredient in Hyplafin is finasteride. According to regulatory sources, this substance is available under other brand names used for different conditions, such as Propecia and Proscar.

Q: Is there a point at which Hyplafin should reach its full expected effect?

Official product information indicates that treatment is intended for continuous, long-term use. An initial beneficial response to the drug may not be assessed until three to six months or longer of daily administration.

Q: What signs indicate that Hyplafin is working as described in the clinical studies?

Studies have examined the effects of the drug by measuring changes in validated indices of disease activity and patient-reported physical function scores. For prostate conditions, official information indicates the drug's action is associated with a reduction in prostatic volume.

Q: Is Hyplafin intended to cure the condition, or is it primarily for symptom management?

Hyplafin is classified as an enzyme inhibitor that works to modulate the hormonal environment by lowering levels of dihydrotestosterone (DHT). This targeted action is typically associated with the long-term management of symptoms and conditions driven by DHT, rather than a cure.

Q: Are there official guidelines for when a person should consider discontinuing Hyplafin?

Regulatory documents state that if use of the drug is stopped, any effects observed typically begin to reverse within six to twelve months. Official information does not provide explicit criteria for when to stop. Patient treatment plans are typically subject to regular review by a healthcare provider.

Q: Is it true that Hyplafin is recommended to be taken at a specific time of day?

Hyplafin is taken once daily, and official documents note that the tablet may be taken with or without food. The main instruction is to maintain intake at a consistent time each day.

Q: Does Hyplafin affect the liver or kidney function over time?

No dosage adjustment is necessary for patients with kidney impairment. However, official information notes that use requires caution in patients with pre-existing liver function abnormalities because the drug is extensively metabolized by the liver.

Q: How quickly do side effects from Hyplafin typically go away after stopping the drug?

Studies and post-marketing experience indicate that some sexual adverse effects, such as decreased libido and erectile dysfunction, have been reported to persist after discontinuation of treatment. Official information does not specify a typical resolution time for all other side effects.

Q: Is it safe to take over-the-counter pain relievers with Hyplafin?

Official prescribing information states that no drug interactions of clinical importance have been identified with several commonly co-administered medicines, including Antipyrine. Official documents emphasize that a healthcare provider should be aware of all medications being taken, including non-prescription pain relievers.

Q: Are there known drug classes that interact dangerously with Hyplafin?

Hyplafin is primarily metabolized by a liver enzyme called CYP3A4. Co-administration with strong inhibitors or inducers of this enzyme is expected to alter the drug's concentration in the blood. Caution is also advised against taking Hyplafin with other 5-alpha reductase inhibitors due to potential additive effects.

Q: What kind of research studies were conducted before Hyplafin was approved?

Official information indicates that the drug was studied in large-scale clinical trials. These studies measured efficacy using both primary outcomes, such as changes in disease activity indices, and secondary outcomes, including patient-reported physical function scores.

Q: Why is Hyplafin a prescription-only medicine?

Hyplafin is a prescription-only medicine due to its hormonal mechanism of action and the necessary medical oversight required for its use. Official regulatory warnings address serious safety risks, including the need for Prostate Specific Antigen (PSA) monitoring and the potential for severe fetal harm.

Q: What is the difference between the brand name Hyplafin and its generic form?

The brand name Hyplafin and its generic counterpart, Finasteride, contain the exact same active pharmaceutical ingredient. Both are subject to the same strict regulatory standards for quality, safety, and effectiveness.

Q: What evidence is available about the long-term effects of Hyplafin use (over 5 years)?

Clinical trials have included research examining the effects of continuous daily use for periods of several years. These studies reviewed participant safety reports and adverse events over the long term.

Q: What does it mean if Hyplafin has a Boxed Warning in official documents?

A Boxed Warning, sometimes referred to as a Black Box Warning, represents the highest level of regulatory warning in official prescribing information. It is intended to draw attention to serious or potentially life-threatening risks associated with the drug's use.

Q: Does Hyplafin cause weight gain or weight loss?

Weight changes are not listed among the most common adverse effects in large clinical trials. However, regulatory review of post-marketing data indicates that unusual weight gain or loss has been reported as an adverse event with unknown incidence.

Q: Does Hyplafin affect sleep patterns or cause insomnia?

Sleep-related side effects, such as insomnia or difficulty falling asleep, are generally not listed among the frequently reported adverse events in large-scale clinical trials.

Q: Can Hyplafin cause problems with driving or operating machinery?

Regulatory documents explicitly state that there is no information to suggest that Hyplafin affects a person's ability to drive or use machines.

Q: Does Hyplafin contain lactose, gluten, or other common allergens?

Official information on the composition of the tablets indicates that the 5 mg formulation of the active ingredient contains lactose. The complete list of inactive ingredients is detailed in the full product information.

Q: Can Hyplafin interact with or affect the efficacy of hormonal birth control?

Hyplafin is strictly indicated only for adult males. While experts generally agree the drug is not thought to stop hormonal contraception from working, regulatory caution exists regarding its presence in semen.

Q: Can people with pre-existing heart conditions use Hyplafin?

The drug is not specifically contraindicated for heart conditions. However, regulatory documents describe potential interactions that may exist with certain medications often prescribed for heart conditions, such as nitrates.

Q: What does the term 'contraindication' mean when related to Hyplafin?

A contraindication is a condition or factor that absolutely prohibits the use of a medical treatment because the potential harm would outweigh any possible benefit. For Hyplafin, being female or pregnant are listed as contraindications.

Q: What is known about taking Hyplafin during pregnancy or while breastfeeding?

Hyplafin is contraindicated in women who are or may become pregnant due to the risk of causing external genital abnormalities in a male fetus. The drug is not indicated for use while breastfeeding.

How should Hyplafin be stored and disposed of?

How to Store and Dispose of Hyplafin?

The official storage conditions for Hyplafin (Finasteride tablets) require maintaining a controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be kept in its original, closed container to ensure stability and should not be stored in humid areas, such as a bathroom.

Child Safety and Handling

It is mandatory to keep Hyplafin out of the sight and reach of children.

Regulatory labeling specifies that the tablets must not be handled by women who are pregnant or who may become pregnant due to the risk of absorption.

Disposal Instructions

Expired or unused tablets must be disposed of correctly. Do not flush the medication down a toilet or pour it into a drain. Disposal should follow official guidelines, such as utilizing a medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hyplafin found in:

A-Z Index: